en · de · es
methods-notes.peptides9002.com › News › Receptor Mechanism And Secretagogue Action — Beginner to Advanced

Receptor Mechanism And Secretagogue Action — Beginner to Advanced

By Editorial Desk · published 2026-01-14 · last reviewed 2026-02-07 · News

somatotroph comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-02-07. Numbers and descriptions here follow the published literature rather than marketing material.

Receptor Mechanism and Secretagogue Action

At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.

One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.

Background and Structural Identity

Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.

Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.

The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.

Ipamorelin at a glance

PropertyValueNotes
Molecular classSynthetic pentapeptideChain of five amino acid residues
Molecular massApproximately 712 DaConsistent with a five-residue chain
Receptor targetGHS-R1aGrowth hormone secretagogue receptor
Primary actionGrowth hormone releasePituitary somatotroph stimulation
Research originDeveloped in the 1990sSmall-peptide secretagogue program

背景与受体作用机制

在机制层面,ipamorelin 与生长激素促分泌受体 1a 型结合,该受体也介导胃饥饿素的多种效应。受体激活后,细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱,它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到,但人体数据仍然有限。

现有文献多来自小规模、短期的研究,涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏,以及重复给药后效应是否衰减,仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大,因此结论外推需谨慎。关于临床获益的确切证据尚不充分,需要更大规模的对照试验来澄清。

Related pages on this site

Receptor Selectivity and Secretagogue Signaling

Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.

Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.

Reference notes

=== Oxidation === The oxidation of isatin using hydrogen peroxide (Baeyer–Villiger oxidation) or chromic anhydride yields isatoic anhydride, a compound widely used either in herbicide products and in medicinal chemistry. The use of peroxydisulfuric acid gives rise to 1,4‑benzoxazine compounds.

When signalled the Tobruk garrison would break out and move south-east towards the advancing Allied forces. The operation was largely successful for the Allies, and the siege was broken. The Rhodesians of the LRDG took part in raids on Axis rear areas during the operation, ambushing Axis convoys, destroying Axis aircraft and pulling down telegraph poles and wires.

Bitcoin wallets were the first cryptocurrency wallets, enabling users to store the information necessary to transact bitcoins. The first wallet program, simply named Bitcoin, and sometimes referred to as the Satoshi client, was released in 2009 by Nakamoto as open-source software. Bitcoin Core is among the best known clients. Forks of Bitcoin Core exist such as Bitcoin Unlimited. Wallets can be full clients, with a full copy of the blockchain to check the validity of mined blocks, or lightweight clients, just to send and receive transactions without a local copy of the entire blockchain. Third-party internet services, called online wallets or hot wallets, store users' credentials on their servers, making them susceptible of hacks. Cold storage protects bitcoins from such hacks by keeping private keys offline, either through specialized hardware wallets or paper printouts.

For services to Health Care. Arthur Derek Hill. For services to Art. Jenny Hughes, , Chairman, Riverside Mental Health NHS Trust. For services to Health. Kenneth Wesley Jarrold, Director of Human and Corporate Resources, NHS Executive, Department of Health. George MacDonald Kennedy, Chairman, Smiths Industries Medical Systems. For services to the Health Care Industry and to Export. Cecil Gordon Knight, , Headteacher, Small Heath School, Birmingham. For services to Education. Simon Timothy Lee. For political service. Thomas Peter Ruffell Laslett. For services to the Cambridge Group for the History of Population and Social Structure. Robert Noyes Lawton. For services to Agriculture in Wessex. Martyn John Dudley Lewis, Chair, Drive for Youth and Youthnet UK. For services to Young People and to the Hospice Movement. Francis David Lindley Loy, lately Chairman, Provincial Stipendiary Magistrates' Association. John Lumsden, Chief Executive, Motherwell Bridge Group. For services to the Engineering Industry. Thomas George Mackey. For services to Urban Regeneration. Colin Barry Manchip, lately Director, Immigration Service (Enforcement), Home Office. Brenda Mary McLaughlin. For services to the community and to Health Care. Elizabeth Mary McLoughlin, Head of Civilian Management (Policy), Ministry of Defence. James David Frederick Miller, Chairman, Scottish Qualification Authority. For services to Education. Dominic Charles Bernard Morris, lately Deputy Head, Policy Unit, 10 Downing Street. Richard Brian Mouatt, lately Chief Dental Officer, Department of Health.

=== Early observational studies === From the 1890s onwards, associations of tobacco use with cancers and vascular disease were regularly reported. In 1930, Fritz Lickint of Dresden, Germany, published a meta-analysis citing 167 other works to link tobacco use to lung cancer. Lickint showed that people with lung cancer were likely to be smokers. He also argued that smoking tobacco was the best way to explain the fact that lung cancer struck men four or five times more often than women (since women smoked much less), and discussed the causal effect of smoking on cancers of the liver and bladder.

Sources: en.wikipedia.org

Notes from published material

== Disorders and conditions == Numerous reports have been published indicating that the glutamate/GABA–glutamine cycle is compromised in a variety of neurological disorders and conditions. Biopsies of sclerotic hippocampus tissue from human subjects with epilepsy have shown decreased glutamate–glutamine cycling. Another pathology in which the glutamate/GABA–glutamine cycle might be compromised is Alzheimer's disease; NMR spectroscopy showed decreased glutamate neurotransmission activity and TCA cycling rate in patients with Alzheimer's disease. Hyperammonemia in the brain, typically occurring as a secondary complication of primary liver disease and known as hepatic encephalopathy, is a condition that affects glutamate/GABA–glutamine cycling in the brain. Current research into autism also indicates potential roles for glutamate, glutamine, and/or GABA in autistic spectrum disorders.

=== Identification of Protopodocarpoxylon === Protopodocarpoxylon is an extinct genus of conifer tracheophytes, now often found as fossilized woods. In a 2007 study, extraction and identification of biomarkers from fossil woods collected in south-central Poland allowed for the identification of the sample as Protopodocarpoxylon Eckhold. Samples of the wood were collected from clays and carbonate concretions then cleaned of contaminants before being pulverized, and the organics extracted. The extracts were derivatized with TMS and then subjected to gas chromatography-mass spectrometry (GC-MS) analysis. Multiple abietanes were detected in the analyzed samples, with ferruginol, sugiol, simonellite, and dehydroabietane present in all four of the samples tested. Sugiol and ferruginol were both detected as unaltered natural products. There was a dramatic difference in detected abundance of sugiol and ferruginol in samples that were more oxidized, but the biomarkers were still detectable in both cases. The unknown fossil wood samples were determined to contain aliphatic lipids (n-alkanols and n-alkanoic acids), diterpenoids (abietanes, labdanes, and totaranes), triterpenoids (lupane and hopane), and steroids. The presence of long chain n-alkanes, ferruginol, sugiol, and dehydroabietic acid were considered and the sample was determined to be a conifer plant, in either the Podocarpaceae, Cupressaceae, or Araucariaceae family.

Trehalose is a sugar derived from two molecules of glucose. Trehalose is a disaccharide formed by a 1,1-glycosidic bond between two α-glucose units. It is found in nature as a disaccharide and also as a monomer in some polymers. Two other stereoisomers exist: α,β-trehalose, also called neotrehalose, and β,β-trehalose, also called isotrehalose. Neither of these alternate isomers has been isolated from living organisms, but isotrehalose has been found in starch hydroisolates. Some bacteria, fungi, plants and invertebrate animals synthesize trehalose as a source of energy, and to survive freezing and lack of water.

== Biography == Leonard Thompson was born on Pickering Street near the Beaches neighbourhood of Toronto on 17 July 1908, to parents Harold and Florence Thompson. He was diagnosed with diabetes mellitus, and was first treated at the Hospital for Sick Children before being transferred to the care of physicians Andrew Almon Fletcher, Duncan Archibald Graham, and Walter Ruggles Campbell. Thompson received his first injection in Toronto, Ontario, on 11 January 1922, at 13 years of age. Thompson's first dose had an apparent impurity which caused an allergic reaction. A refined process was quickly developed to concentrate the pancreatic extract. Twelve days later, on 23 January, he began a two-week series of daily injections that rapidly improved his health, allowing him to live until dying of bronchopneumonia at age 26. Until insulin was made clinically available, a diagnosis of diabetes was a death sentence, more or less quickly (usually within months, and frequently within weeks or days).

Sources: en.wikipedia.org

Background from the literature

For more than ten years, the U.S. has been funding Plan Colombia, which aims to combat illegal drugs production in the country, especially the growing of coca, the plant from which cocaine is produced. Former President Obama's top drug policy adviser, R. Gil Kerlikowske, announced a drug plan in May 2010 emphasizing prevention and treatment in the United States.

== Release == PYY is found in L cells in the mucosa of gastrointestinal tract, especially in ileum and colon. Also, a small amount of PYY, about 1-10%, is found in the esophagus, stomach, duodenum and jejunum. PYY concentration in the circulation increases postprandially (after food ingestion) and decreases by fasting. In addition, PYY is produced by a discrete population of neurons in the brainstem, specifically localized to the gigantocellular reticular nucleus of the medulla oblongata. C. R. Gustavsen et al. had found PYY-producing cells located in the islets of Langerhans in rats. They were observed either alone or co-localized with glucagon or PP. PYY is released by the L-cells of the gastrointestinal tract following food intake, and there are two main endogenous forms: PYY1-36 and PYY3-36. PYY1-36 is rapidly processed by the enzyme DPP4 to the 34-amino acid peptide PYY3-36. DPP4 hydrolyses PYY and removes the first two amino acids, tyrosine and proline, at the N-terminal, which changes the receptor selectivity. As a result of this, PYY3-36 has a high selectivity for the Y2-receptor, compared to PYY1-36 which has selectivity for the Y1, Y2, and Y5 receptors. It is thought that the Y1 receptor requires both the C-terminus and N-terminus for recognition, binding and then subsequent activation. The Y2 receptor is thought to have a smaller receptor site and also only requires the C-terminus for recognition. This could explain the reduced affinity for PYY3-36 on any other Y receptor other than Y2.

== Society and culture == In the US, fillers are approved as medical devices by the Food and Drug Administration (FDA) and the injection is prescribed and performed by a provider. What defines a qualified dermal injection provider varies by country and is a point of debate between board-certified doctors and injectors who operate under cosmetic or aesthetician licenses. Fillers are not to be confused with neurotoxins such as Botox. Fillers are not approved for certain parts of the body where they can be unsafe, including the penis. In the European Economic Area and the UK, fillers are non-prescription medical devices that can be injected by anyone licensed to do so by the respective medical authorities. They require a CE mark, which regulates adherence to production standards, but does not require any demonstration of medical efficacy. As a result, there are over 140 injectable fillers in the UK/European market and only six approved for use in the US. In China, the NMPA (formerly CFDA) has also issued guidance to regulate injectable fillers.

=== Health and death === On September 16, 1999, Barker was in Washington, D.C., to testify before Congress regarding proposed legislation that would ban captive elephants from traveling shows, such as circuses. While preparing for the presentation, Barker experienced what he called clumsiness in his right hand. Barker was admitted to George Washington University Hospital and diagnosed with a partially blocked left carotid artery. He underwent carotid endarterectomy to remove the blockage. The procedure went well enough that Barker was able to return to work within the month. Three years later, Barker had two additional health crises after taping the 30th-season finale of The Price is Right. While lying in the sun on May 30, 2002, he experienced a stroke and was hospitalized; six weeks later, on July 11, Barker underwent prostate surgery. Both hospitalizations occurred at George Washington University Hospital in Washington, D.C. and both surgeries were successful. Barker had several mild bouts with skin cancer, a result of his frequent tanning. Barker consulted a dermatologist regularly to make sure any cancers were caught and removed before they spread; they did not pose a threat to his life. During a televised interview, Barker told viewers, "I urge anyone who has spent some time in the sun, whether you're doing it now or not, go to a dermatologist once a year." On October 20, 2015, two police officers passing Barker's Los Angeles-area home saw him trip and fall on a sidewalk.

Anchoring fibrils (composed largely of type VII collagen) extend from the basal lamina of epithelial cells and attach to the lamina reticularis (also known as the reticular lamina) by wrapping around the reticular fiber (collagen III) bundles. The basal lamina and lamina reticularis together make up the basement membrane. Anchoring fibrils are essential to the functional integrity of the dermoepidermal junction.

Sources: en.wikipedia.org

Frequently asked questions

What receptor does ipamorelin act on?

It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.

How does ipamorelin differ from earlier secretagogues?

In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.

Is the mechanism of action fully understood?

The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.

What type of molecule is ipamorelin?

It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.

Network